Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2020 Oct;25(5):e12727.
doi: 10.1111/hel.12727. Epub 2020 Jul 23.

A panel of stomach-specific biomarkers (GastroPanel®) for the diagnosis of atrophic gastritis: A prospective, multicenter study in a low gastric cancer incidence area

Nicolas Chapelle  1   2   3 , Pawel Petryszyn  4 , Justine Blin  2   3   5 , Maxime Leroy  6 , Catherine Le Berre-Scoul  2   3 , Iva Jirka  1 , Michel Neunlist  2   3 , Driffa Moussata  7 , Dominique Lamarque  8 , Raphael Olivier  1   9 , David Tougeron  9 , Jean-François Mosnier  2   10 , Tamara Matysiak-Budnik  1   2   3
Affiliations
Multicenter Study

A panel of stomach-specific biomarkers (GastroPanel®) for the diagnosis of atrophic gastritis: A prospective, multicenter study in a low gastric cancer incidence area

Nicolas Chapelle et al. Helicobacter. 2020 Oct.

Abstract

Background: Analysis of serum biomarkers for the assessment of atrophic gastritis (AG), considered as gastric precancerous lesion, is of growing interest and recommended by current guidelines. Our aim was to evaluate the diagnostic performance of a panel of biomarkers (GastroPanel®) for the detection of AG in France, a country of a low gastric cancer (GC) incidence.

Material and methods: In this prospective, multicenter, cross-sectional study, consecutive patients considered at increased risk of GC and undergoing upper endoscopy with gastric biopsies were included. Blood samples were collected for the analysis of GastroPanel® (association of Pepsinogens I and II, Gastrin-17, and Helicobacter pylori serology) using ELISA. The results of GastroPanel® were compared to the results of histology considered as the reference.

Results: Between 2016 and 2019, 344 patients (148 cases with AG, 196 controls without AG) were included. Sensitivity, specificity, positive, and negative predictive values for the detection of AG by GastroPanel® were of 39.9% (95% CI 31.9; 48.2), 93.4% (95% CI 88.9; 96.4), 81.9 (95% CI 71.1; 90.0), and 67.3 (95% CI 61.4; 72.8), respectively. The sensitivity was significantly higher for the detection of severe AG [60.8% (95% CI 46.1; 74.6) P = .015] and corpus AG [61.0% (95% CI 49.2; 72.0), P = .004]. Diagnostic performances of GastroPanel® tended to be better than those of Pepsinogen I alone, but the difference did not reach statistical significance (P = .068).

Conclusion: Serum pepsinogen and GastroPanel® tests show promising results for the detection of AG, especially of corpus AG and severe AG, in patients at high risk of GC in France.

Keywords: atrophic gastritis; diagnostic performance; gastropanel; noninvasive markers.

PubMed Disclaimer

References

REFERENCES

    1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68(6):394-424.
    1. Chapelle N, Manfredi S, Lepage C, et al. Erratum to: trends in gastric cancer incidence: a period and birth cohort analysis in a well-defined French population. Gastric Cancer. 2016;19(2):682.
    1. Correa P, Haenszel W, Cuello C, et al. A model for gastric cancer epidemiology. Lancet Lond Engl. 1975;2:5875.
    1. Correa P. A human model of gastric carcinogenesis. Cancer Res 1988;48:3554.
    1. de Vries AC, van Grieken NCT, Looman CWN, et al. Gastric cancer risk in patients with premalignant gastric lesions: a nationwide cohort study in the Netherlands. Gastroenterology. 2008;134(4):945-952.

MeSH terms

LinkOut - more resources